Trial reportCA: a cancer journal for clinicians
Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open-label, noninferiority, multicenter, randomized phase 3 trial.
3 registry-linked trialsAbstract readClinical Trial, Phase IIIComparative StudyEquivalence Trial
In one paragraph
Trial report in CA: a cancer journal for clinicians. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 22 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Reducing Target Volumes in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy: A Phase 3, Multicentre, Non-inferiority, Randomised Controlled Trial
A Randomized, Open-Label, Non-Inferiority Phase III Multicenter Clinical Trial Comparing Reduced-Dose to Standard-Dose Prophylactic Irradiation for Low-Risk Clinical Target Volume (CTV) in the Treatment of Nasopharyngeal Carcinoma.
Individualized Versus Standard Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma: A Non-inferiority, Phase III, Multicenter, Prospective, Randomized Controlled Trial
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Immune checkpoint inhibitor integration in locoregionally advanced nasopharyngeal carcinoma: a prospective evidence synthesis on efficacy, safety, and therapeutic optimization.Frontiers in immunology · 2026Pooled it
- Mesenchymal stem cell therapy for radiation-induced xerostomia: a systematic review and network meta-analysis.Stem cell research & therapy · 2025Pooled it
- Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open-label, noninferiority, multicenter, randomized phase 3 trial.CA: a cancer journal for cliniciansTrial
- Advances in the Research of Nasopharyngeal Carcinoma: A Perspective.Cancer innovation · 2026Review
- Beyond theJCO precision oncology · 2026Review
- Synthetic CT-enabled weekly adaptive radiotherapy for nasopharyngeal carcinoma: Optimizing plan adaptation triggers through volumetric-dosimetric monitoring.Journal of applied clinical medical physics · 2026Article
- PPP2R2C confers radioresistance in nasopharyngeal carcinoma by suppressing ferroptosis via RPS27L stabilization.Cell death & disease · 2026Article
- Adaptive radiotherapy based on nodal response to induction chemotherapy in nasopharyngeal carcinoma: a retrospective dose de-escalation analysis.Translational cancer research · 2026Article
- De-Escalation Strategies in Nasopharyngeal Carcinoma.Current oncology reports · 2026Review
- Green Nanodrugs: Research Progress and Challenges of Plant-Derived Nanovesicles in Tumor Treatment.Pharmaceutics · 2026Review
- Harnessing the immune microenvironment: advances in nasopharyngeal carcinoma immunotherapy.Cell death discovery · 2026Review
- Non-Gaussian diffusion MRI using CTRW and FROC models for early treatment response assessment in nasopharyngeal carcinoma.BMC medical imaging · 2026Article
- Development of nasopharyngeal carcinoma target delineation: from two-dimensional radiotherapy to adaptive precision radiotherapy.Journal of Cancer · 2026Review
- Nanotechnology-based shikonin delivery strategies for modulating the tumor immune microenvironment efficacy.Drug delivery and translational research · 2026Review
- Strategies and challenges of toxicity reduction in nasopharyngeal carcinoma in the era of precision radiotherapy: from paradigm shift to integrated decision-making.Frontiers in oncology · 2026Review
- Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel Compared to Docetaxel Plus Nedaplatin as Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma: A Propensity Score Matching Analysis.Cancer management and research · 2026Article
- Beyond Standard Radiotherapy: an AI-Driven Framework for Personalized Radiotherapy with a Four-Step Classification in Head and Neck Squamous Cell Carcinoma (HNSCC) Patients.Current oncology reports · 2025Review
- Targeting oncogenic acetyltransferase NAT10 to overcome anti-PD-1 resistance in nasopharyngeal carcinoma.Journal for immunotherapy of cancer · 2025Article
- Clinical benefits of enhanced 3D-NEVERview sequence in MRI simulation for nasopharyngeal carcinoma patients received radiotherapy.BMC cancer · 2025Article
- Preliminary exploration of radiotherapy timing following induction chemoimmunotherapy in unresectable locally advanced esophageal squamous cell carcinoma: a single-center retrospective study.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Ling-Long TangDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.ORCID https://orcid.org/0000-0002-8561-1454
Lin ChenDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.ORCID https://orcid.org/0009-0000-0297-806X
Gui-Qiong XuNasopharyngeal Head and Neck Carcinoma Radiotherapy Department, Zhongshan City People's Hospital, Zhongshan, China.
Ning ZhangDepartment of Nasopharyngeal Oncology, First People's Hospital of Foshan, Foshan, China.
Cheng-Long HuangDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.ORCID https://orcid.org/0009-0007-9019-0280
Wen-Fei LiDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.ORCID https://orcid.org/0000-0001-7605-3609
Yan-Ping MaoDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Guan-Qun ZhouDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Feng LeiNasopharyngeal Head and Neck Carcinoma Radiotherapy Department, Zhongshan City People's Hospital, Zhongshan, China.
Lu-Si ChenDepartment of Nasopharyngeal Oncology, First People's Hospital of Foshan, Foshan, China.
Shao Hui HuangDepartment of Radiation Oncology, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada.
Lei ChenDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Yu-Pei ChenDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.ORCID https://orcid.org/0000-0002-0010-3494
Yuan ZhangDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.ORCID https://orcid.org/0000-0002-7141-1208
Xu LiuDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.ORCID https://orcid.org/0000-0003-4827-5524
Cheng XuDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.ORCID https://orcid.org/0000-0002-4503-6029
Yin ZhaoDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.ORCID https://orcid.org/0000-0001-7007-2999
Ji-Bin LiClinical Trials Center, Sun Yat-sen University Cancer Center, Guangzhou, China.
Na LiuDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.ORCID https://orcid.org/0000-0001-8654-3636
Fang-Yun XieDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.ORCID https://orcid.org/0000-0003-4800-6025
Rui GuoDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.ORCID https://orcid.org/0000-0003-1683-0837
Ying SunDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.ORCID https://orcid.org/0000-0002-5888-2929
Jun MaDepartment of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.ORCID https://orcid.org/0000-0002-1137-9349
Funding
Audiology Development Foundation of China ADFC-XM-2022003Cancer Innovative Research Program of Sun Yat-sen University Cancer Center CIRP-SYSUCC-0005Cancer Innovative Research Program of Sun Yat-sen University Cancer Center CIRP-SYSUCC-0046Guangzhou Municipal Health Commission 2023P-GX04National Natural Science Foundation of China 82172870National Natural Science Foundation of China 82430085National Natural Science Foundation of China U24A20725Noncommunicable Chronic Diseases-National Science and Technology Major Project 2024ZD0520701Overseas Expertise Introduction Project for Discipline Innovation 111Project, B14035Sun Yat-sen University Clinical Research 5010 Program 2019014
Abstract
backgroundNearly 90% locoregionally advanced nasopharyngeal carcinoma (LANPC) responds to induction chemotherapy (IC) with significant tumor volume shrinkage. Radiotherapy always follows IC, and reduced volume has been proposed. However, the efficacy and safety of reduced-volume radiotherapy is uncertain.
methodsIn this multi-center, noninferiority, randomized, controlled trial, patients with LANPC who completed IC were randomly assigned (1:1) to receive reduced-volume radiotherapy based on post-IC tumor volume (Post-IC group) or conventional volume radiotherapy based on pre-IC tumor volume (Pre-IC group). The primary endpoint was locoregional relapse-free survival, with a noninferiority margin of 8%. Secondary endpoints comprised adverse events, and quality of life (QoL).
resultsBetween August 7, 2020, and May 27, 2022, 445 patients were randomly assigned to Post-IC (n = 225) or Pre-IC (n = 220) groups. The average volume receiving radical dose was 66.6 cm
conclusionsIn this trial, reduced-volume radiotherapy was noninferior to conventional volume radiotherapy in locoregional relapse-free survival, and was associated with lower toxicities and improved QoL. (ClinicalTrials.gov identifier NCT04384627).
Indexed as
Induction ChemotherapyNasopharyngeal CarcinomaNasopharyngeal NeoplasmsRadiation InjuriesAdultAgedFemaleHumansMaleMiddle AgedQuality of LifeTumor Burdenclinical trialnasopharyngeal carcinomanoninferiorityreduced‐volume radiotherapy
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.